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Abstract 
A novel nanocarrier based on functionalized mesoporous silica nanoparticles able to transport 
a non-toxic pro-drug and the enzyme responsible for its activation has been presented. This 
nanodevice is able to generate in situ cytotoxic species once accumulated in the tumoral cell. 
Enzymes are sensitive macromolecules which can suffer denaturalization in biological media 
due to the presence of proteases or other aggressive agents. Moreover, the direct attachment 
of enzymes to the silica surface could reduce their activity by conformational changes or 
active site blockage. For these reasons, in order to create a robust system able to work in 
living organisms, the enzymes were previously coated with a protective polymeric shell which 
allows the attachment on the silica surface preserving their activity. The efficacy of this 
hybrid nanodevice for antitumoral purposes has been tested against several human tumoral 
cells as neuroblastoma and leukemia showing significant efficacy. It converts this device in a 
promising candidate for further in vivo studies for oncology therapy. 
 
1. Introduction 
The development of novel nanodevices able to transport and release cytotoxic agents into 
tumoral tissues constitutes one of the most important field of the modern nanomedicine.[1] 
One of the main reasons for this interest is the fact that nanoparticles tend to be preferentially 
accumulated within tumoral tissues by a passive mechanism, called EPR effect (Enhance 
Permeation and Retention).[2] This effect is based on the distinct blood vessel architecture 
present in solid tumors which is characterized by the presence of wide interendothelial 
junctions, large number of fenestrations and transendothelial pores with diameters as large as 
several hundred nanometers.[3] Thus, nanoparticles injected in the blood stream will pass 
through the fenestrations present in the tumoral vessels, while they are not able to cross 
through the healthy blood vessel walls.  
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In the recent years, a vast number of nanocarriers for drug delivery purposes have been 
described.[4] Among them, mesoporous silica particles are promising candidates due to their 
unique properties such as tuneable size, shape and porosity, high loading capacity, robustness 
and easy functionalization.[5] These characteristics provide unique opportunities to 
encapsulate different drugs, ranging from small molecules to therapeutic macromolecules.[6] 
In addition, their toxicity is low[7] showing good hemocompatibility, which is a must for 
intravenous administration.[8] The transport of highly toxic antitumoral drugs usually requires 
the development of carriers able to avoid the premature release of the loaded drugs before 
reaching the target, in order to avoid systemic toxicity.[9] This neccesity introduces high 
complexity in the synthesis of the carriers and therefore, it hampers the clinical application of 
these devices because their approval requires extensive safety evaluation of all the 
components.[10] In this work, we describe a simpler strategy based on the development of a 
novel nanocarrier capable to deliver a harmless prodrug into tumoral cells and once there, 
transform it into cytotoxic species which provoke the destruction of the malignat cell (Figure 
1).  
 
 
Figure 1. Schematic illustration of the in situ cytotoxic generation for antitumoral therapy 
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The most common strategy for the activation of prodrugs requires the presence of certain 
enzymes overexpressed in the target tissue.[11] However, this approach is limited in many 
cases by the scarce concentration of the activating enzyme into the target zone, which is not 
sufficient to generate enough amounts of drug necessary to provoke a significative 
response.[12] Moreover, there are many prodrugs for which the activating enzyme is not 
present. In this case, it is necesary to co-administrate the enzyme required for its activation or 
to introduce the gene required for its synthesis into the target cells.[13] Our system is based on 
a functionalized mesoporous silica nanoparticle loaded with a non-toxic prodrug, that is 
retained by electrostatic interactions within the porous silica network. The enzyme 
responsible for the drug activation is covalently anchored on the external surface. Indol-3-
acetic acid (IAA) is a plant growth hormone which has been selected as pro-drug. It can be 
oxidised by the enzyme Horseradish peroxidase (HRP) producing cytotoxic compounds, 
mainly hydroxyl and reactive oxygen species (ROS), able to destroy human cancer cells by 
membrane and DNA damage.[14] IAA is not easily oxidized by mammalian peroxidases and, 
therefore, it is well tolerated in humans and even presents positive effects such as an increase 
in the phagocytic capacity of neutrophils[15] or antioxidant activity.[16] Therefore, the necessity 
to avoid the premature release of the housed pro-drug from the silica matrix is not as 
important as in the case of transporting conventional cytotoxic compounds. HRP also exhibits 
low toxicity in humans.  
Direct attachment of enzymes on surfaces usually produces a significant reduction in their 
activity due to active site blockage or conformational changes during the process.[17] In 
addition, proteins usually present low stability in biological media due to the presence of 
proteases or other aggressive agents.[18] In order to overcome these limitations, the enzymes 
used in our device were previously coated with a polymeric capsule engineered to allow the 
grafting to the mesoporous surface and at the same time preserving their activity for longer 
times. Finally, the capacity of this novel nanocarrier to destroy human tumoral cells of 
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neuroblastoma (NB1691-luc), a solid tumor which present a poor prognosis and B cell 
precursor leukemia (NALM-6), as a non-solid tumor model, was tested showing a significant 
efficacy. 
 
2. Results and Discussion 
2.1 Synthesis of amine-functionalized mesoporous silica nanocarriers 
 
In order to improve the loading and retention capacity of IAA within the pore network, 
mesoporous silica nanoparticles were synthesized in the presence of 
aminopropyltriethoxysilane (APTES) as functionalizing agent and tetraethylorthosilane 
(TEOS) as silica precursor, following a co-condensation method, which allows the production 
of homogeneously functionalized particles.[19] The presence of amino groups in the silica pore 
network is expected to improve the retention of IAA (pKa 4.75) at physiological pH, due to 
electrostatic interactions between the positively charged mesoporous particle surface with the 
anionic pro-drug. The maximal amount of functional groups which can be incorporated by a 
co-condensation method is limited by decrease of the mesoscopic order of the products and 
higher homocondensation reactions of the functionalized silica precursor with increasing the 
concentration.[19] In our case, three batches of particles were synthesized adding a mixture of 
APTES/TEOS, with different APTES proportion (10%, 20% and 30% of APTES molar ratio). 
The particles as synthesized were called MSN-10N, MSN-20N and MSN-30N respectively, 
according to the amount of APTES employed in the process. After the synthesis the surfactant 
was removed by ionic exchange using a solution of ammonium nitrate. The amount of amino 
groups was determined by thermal analysis being 5, 10 and 24% respectively which confirms 
the presence of a higher amount of amino groups on the silica surface and within the pore 
network when more APTES was added to the reaction media (Figure S1). The size of each 
batch of particles was determined by dynamic light scattering (DLS) showing that the size 
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distribution shifted to higher values (124 to 164 nm) when the concentration of APTES 
increased (Figure 2a). The average size of all batches was suitable for drug delivery 
applications in order to facilitate the cellular uptake.[20] The size distribution of each batch was 
confirmed by SEM and TEM (Figure 2c-d). 
 
 
Figure 2. a) DLS and b) Z potential measurements of MSN materials. c-d) SEM and TEM 
images of MSN-30N (SEM and TEM images MSN-10N, 20N in Figure S2) 
 
Zeta potential measurements in water of these particles show drastic change on the superficial 
charge from -16 mV, in the case of MSN-10N, to +44 and +39 with MSN-20N and MSN-30N 
respectively (Figure 2b). Small-angle XRD pattern of the three batches show that the 
characteristic profile of MCM-41 materials is not affected by the use of higher amounts of 
APTES (Figure S3). Nitrogen sorption isotherms indicate that the surface areas of these 
particles are comprised between 900-1200 m2•g-1, with pore size distribution around 2.1-2.8 
nm (Table S1). Finally, the significant increase of the C-H (2900 cm-1) and N-H (1520 cm-1) 
bands in the FTIR spectra show that higher amounts of amino groups were incorporated when 
the concentration of APTES is augmented (Figure S4). 
2.2. IAA release profile of the nanocarriers 
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In order to select the best material for IAA loading and release, the dried materials were 
soaked separately with IAA solution (25 mg/mL) in phosphate buffer (PB) pH 7.2 during 24 h. 
After that, the materials were filtered and the superficially adsorbed IAA was removed by 
washing with cold buffer. Then, a certain amount of each of the as loaded materials was 
suspended in fresh PB pH 7.2 on a Transwell® permeable support of polycarbonate 
membrane. This membrane allows that small molecules (as IAA) can pass through its pores 
retaining the nanoparticles. Every hour, the liquid of each well was completely replaced by 
fresh buffer and the amount of IAA was determined by HPLC. The results indicate that MSN-
30N is able to retain higher amounts of IAA, showing a loading capacity of 5% w/w, 
compared with MSN-20N and MSN-10N which present 2% and 0.25% w/w respectively 
(Figure S5). Moreover, MSN-30N is able to maintain a sustained release of the prodrug 
during more time. For these reasons, this material was selected for further studies. It is worth 
to point out that these release experiments have been performed replacing totally the media 
with fresh buffer each hour which is better mimicking the real in vivo conditions. 
 
2.3. Synthesis of HRP nanocapsules 
As it has been mentioned above, the aim of this work is to synthesize a material able to 
transport the pro-drug and the enzyme responsible for its activation simultaneously. Thus, this 
system can be able to generate enough amounts of cytotoxic agents once accumulated within 
the tumoral tissue by the EPR effect. However, the effective development of this strategy 
requires finding a suitable way to transport the enzyme through the body towards the tumoral 
mass, which is usually a great challenge. The presence of proteases and other aggressive 
agents both in the bloodstream and organ tissues can digest the proteins before they reach the 
target. Different approaches for transporting proteins have been described, from their 
encapsulation within nanoparticles[21] to the use of nanocarriers to transport the gene which 
encodes the protein into the target cells.[22] Recently, Lu et al. have described a novel 
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methodology for protein delivery which consists in the synthesis of a polymer coating around 
the protein.[23] The resulting polymer-protein nanocapsule was stable against protease 
degradation and was able to be internalized by human cells. 
 
Scheme 1. Synthesis of the nanocarrier MSN-30N-IAA-HRPc. i) acrylic acid N-
hydroxysuccinimide, ii) acrylamide: aminoethyl methacrylate hydrochloride: MBA (8:6.1), 
APS/TMEDA and iii) DSS 
 
In our work, we have applied a slightly modified method for the production of polymer-
coated HRP nanocapsules with amino-functional groups on the external surface (Scheme 1). 
These amino groups allow the further attachment of the enzyme nanocapsules to the 
mesoporous silica surface as is discussed below. The first step was the introduction of 
polymerizable acryloyl groups on the surface of the protein using acrylic acid N-
hydroxysuccinimide ester in pH 8.5 Na2CO3 50mM buffer, which reacts with the free amino 
groups present in the protein. The average amount of acryloyl groups introduced in each 
protein was determined by MALDI-TOF mass spectrometry resulting in approximately 4 
groups per protein (Figure S6). After that, the polymer shell was formed by radical 
polymerization using three different monomers: acrylamide, 2-aminoethyl methacrylate 
hydrochloride (which is responsible for the introduction of amino groups) and N,N´- 
methylene(bisacrylamide) as cross-linker, in molar ratio 8:6:1, respectively. The 
polymerization was initiated adding a solution of ammonium persulfate (APS) and N,N,N´,N´-
tetramethylethylenediamine (TMEDA), yielding the protein-polymer capsule (HRPc) after 90 
min at room temperature. The purification of both HRPa and HRPc was performed by 
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centrifugation using centrifugal filters AMICON® Ultra-2 30K and 50K respectively. It is 
important to note that both the acroylation and polymerization reactions were carried out in 
the presence of 4-dimethylaminoantipyrine (1:10 weight ratio to HRP) as stabilizer to prevent 
protein denaturalization. 
DLS measurements in water indicated a significative increase in the hydrodynamic radius of 
the enzymes, from an average diameter of 4 nm to 8-9 nm, which clearly confirm the 
formation of the polymer coating (Figure 3a). This fact was confirmed by TEM using 
phosphotungstic acid (PTA) as staining agent of the polymer shell. The capsules show an 
average diameter in accordance with the DLS measurements (Figure 3c-d). According to the 
zeta potential measurements in water, the acroylation process scarcely modified the surface 
charge of the native protein while a drastic change from negative to positive values is 
observed when the polymer shell is formed on the protein surface (Figure 3b). This result is 
consistent with the formation of a polymeric coating with free amino groups on the surface 
which are protonated at neutral pH. 
 
Figure 3. a) DLS and b) Zeta potential of HRP native, HRPa and HRPc, c-d) TEM of HRPc 
stained with phosphotungstic acid at different scales 
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In order to ascertain that the enzyme maintains its activity after the polymer coating, the 
enzymatic activity of the HRPc and the native precursor HRP were determined by the method 
developed by Trinder et al.[24] It follows the enzymatic oxidation of phenol by HRP in the 
presence of 4-aminoantipyrinie and hydrogen peroxide. Both activities were similar, which 
clearly indicates that the protein does not suffer significative alterations during the coating 
process (Figure 4). Moreover, HRPc solutions can be stored in the fridge for several weeks, 
without significant loss of activity which evidences that the polymeric shell preserves and 
protects the integrity of the biomolecule. 
 
 
Figure 4. Enzymatic activity of HRP native and HRP capsule 
 
2.4. HRP nanocapsule attachment on mesoporous silica surface 
 
The attachment of the HRPc on the silica surface should be performed keeping inactive the 
enzyme during the process in order to avoid the premature conversion of the prodrug. Native 
HRP requires the presence of oxygen for the catalytic decomposition of IAA.[25] Thus, if 
oxygen is not present in the media or its concentration is low, the decomposition rate of IAA 
should be lower. In order to test this idea, a certain amount of HRPc (100 µg) was added to a 
solution of IAA in the presence or absence of oxygen (using nitrogen atmosphere and 
deoxygenated water). After 2 hours, the amount of IAA was determined by HPLC indicating 
that if the reaction is carried out without oxygen, the concentration of IAA maintains almost 
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equal to the initial (Figure S7). Therefore, the grafting reaction of HRPc on the IAA-loaded 
particles was performed employing suberic acid bis(N-hydroxysuccinimide ester) (DSS) as 
amino-amino homofunctional cross-linker, keeping the reaction under nitrogen atmosphere 
and using buffers previously deoxygenated three times by freeze-pump-thraw cycles with N2. 
The exact amount of HRPc anchored on the particle surface could not be precisely determined 
by TGA because the weight change before and after the grafting reaction is close to 1%. 
According to DLS measurements, the resulting system suffered an increase of around 20 nm 
in the diameter (Figure 5a) and a significative reduction of the zeta potential value, from +39 
mV to +8 mV (data not shown) which indicates that the HRPc has been incorporated on the 
surface of the particles. The attached enzyme nanocapsules were clearly visible by TEM using 
phosphotungstic acid as staining agent (Figure 5b-c). 
 
 
 
Figure 5. a) DLS measurements of MSN-30N and MSN-30N-IAA-HRPc b) and c) TEM of 
MSN-30N-IAA-HRPc stained with phosphotungstic acid 
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In order to be sure that the enzyme capsules attached on the mesoporous surface retain the 
activity after the grafting step, HRPc was also anchored on the surface of empty MSN-30N 
particles in the same conditions. The enzymatic activity of the resulting system was measured 
by the Trinder´s method, as in the previous case. The mesoporous nanoparticles 
functionalized with HRPc (MSN-30N-HRPc) showed an activity of 3-4 U•g-1, which is 
approximately one hundred times lower than the HRPc alone (400 U•g-1 aprox.), which 
confirms that the grafting yield does not exceeds 1%. Moreover, this result indicates that 
HRPc can be covalently anchored on mesoporous particles retaining their activity (Figure S8). 
 
2.5. In vitro cytotoxicity and cellular uptake evaluation 
The antitumoral efficacy of this nanodevice was evaluated in vitro against two human tumoral 
cell lines, neuroblastoma (NB1691-luc) and leukemic (NALM6), due to the great importance 
of this type of tumours in pediatric oncology. The in vitro cytotoxicity study of the system 
was determined by the exposure of both cellular lines to increased amounts of nanomaterials 
in order to establish the minimal concentration required to induce significant cell mortality.  
Cells were incubated for 4 hours to allow the particle internalization, and then washed-out 
with PBS to remove the non-internalized particles and the prodrug released in the 
extracellular medium. Thus, only the effect provoked by the internalized particles will be 
tested. Then, cells were incubated overnight in fresh media. MSN-30N and MSN-30N-IAA 
were employed as controls. Cells incubated with the complete material (MSN-30N-IAA-
HRPc) show rapidly decreasing viability at concentrations ranging from 0.1 to 0.5 mg•mL-1 in 
both cases, whereas MSN-30N and MSN-30N-IAA only present a significant cell viability 
decrease in the case of leukemic cells when the concentration exceeds 1 mg•mL-1 (Figure 6). 
The increased toxicity of the bare material in leukemic cells could be due to the fact that this 
cell line grows suspended in the media being more difficult to completely remove the non-
internalized particles by washing steps after the incubation time.  
  
13 
 
 
Figure 6. Cytotoxicity studies with neuroblastoma and leukemic cells 
 
Thus, the therapeutic window with the complete system (MSN-30N-IAA-HRPc) against these 
tumoral cell lines can be placed around 0.1-0.5 mg•mL-1 where a high cell survival decrease is 
observed whereas the controls did not show any significant negative effect. It is interesting to 
note that higher concentration of free IAA, more than 5 mM, is required to kill neuroblastoma 
cells when they are incubated with a fixed concentration of HRPc (0.01 mg•mL-1). If the cells 
are treated with the native enzyme, no significative mortality was appreciated (Figure S9). 
This result demonstrates that the encapsulation of IAA allows a better internalization within 
the cells improving its efficacy. Additionally, in order to be sure that the toxicity of the 
complete system was not due to the presence of the enzyme capsules, neuroblastoma cells 
were incubated with HRPc and native HRP, as controls, showing that both native enzyme and 
enzyme nanocapsule do not exhibit deleterious effects at the concentration present in the 
mesoporous materials and neither with higher amounts (Figure S10).  
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To visualize the cellular uptake properties of these particles, a new batch of particles without 
IAA (MSN-30N) was labeled with rhodamine B isocyanate (RITC) whereas the enzyme 
capsules were labeled with fluorescein isocyanate (FITC). Then, the capsules were attached 
on the surface of the mesoporous particles following the same grafting procedure. 
Neuroblastoma cells were incubated in the presence of 0.5 mg/mL of these particles during 
four hours and after that time, the excess of non-internalized particles were removed by 
washing. The internalized particles were clearly observed by confocal fluorescence 
microscopy showing co-localization of both enzyme nanocapsules and mesoporous carriers, 
indicating that this nanodevice is able to pass through the cellular membrane (Figure 7). 
 
 
 
Figure 7. Representative confocal images of uptaked particles by neuroblastoma cells: a,e) 
cellular nucleus (stained with DAPI), b,f) FITC-enzyme capsules, c,g) RITC-mesoporous 
particles and d,h) combined images with bright field 
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3. Conclusions 
In conclusion, a novel nanomaterial able to transport a non-toxic prodrug and the enzyme 
responsible for its conversion into cytotoxic compounds has been presented. This nanodevice 
can be internalized by tumoral cells and once there, it can generate enough amounts of 
cytotoxic species to destroy the diseased cells. This presents a novel way to treat tumors 
reducing the side effects of the current antitumoral therapy because it is based on the in situ 
generation of the cytotoxic compounds instead of transporting drugs in the activated state. 
The therapeutic efficacy of this system was evaluated in vitro against human tumoral cell 
lines (neuroblastoma and leukemia). The potential clinical application of these nanodevices 
requires extensive evaluation using animal models in order to determine their safety, 
pharmacokinetic and biodistribution. Further work is ongoing in order to test the efficacy of 
this device in neuroblastoma murine models. 
 
4. Experimental Section 
Reagents. 
Following compounds were purchased from Sigma-Aldrich Inc.: Peroxidase from horseradish 
(HRP) (powder, 250-300 U/mg solid using pyrogallol), indol-3-acetic acid sodium salt, 
suberic acid bis(N-hydroxysuccinimide ester) (DSS), acrylic acid N-hydroxysuccinimide ester, 
2-aminoethyl methacrylate hydrochloride, acrylamide, 4-dimethylaminoantipyrine, N,N´-
methylene(bisacrylamide) (MBA), aminopropyltriethoxysilane (APTES), ammonium 
persulfate (APS), ammonium nitrate, cetyltrimethylammonium bromide (CTAB), tetraethyl 
orthosilicate (TEOS) and N,N,N′,N′-Tetramethylethylenediamine (TMEDA), rhodamine b 
and fluorescein isothiocyanate. These compounds were used without further purification. 
Deionized water was purified by passage through a Milli-Q Advantage A-10 Purification 
System (Millipore Corporation) to a final resistivity of 18.2 MΩ•cm. Acroylated HRP and 
HRP capsules were purified by ultrafiltration using centrifugal filter devices (AMICON® 
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Ultra-2 30K and 50K). All other chemicals (absolute ethanol, acetone, etc.) were of the best 
quality commercially available and they have been employed as received. 
 
Characterization techniques. 
Powder X-ray diffraction (XRD) experiments were performed with a Philips X’Pert 
diffractometer equipped with Cu Kα radiation (wavelength 1.5406 Å). XRD patterns were 
collected in the 2θ range between 0.6º and 8 with a step size of 0.02º and counting time of 5 s 
per step. Fourier transform infrared spectroscopy (FTIR) in a Thermo Nicolet nexus equipped 
with a Goldengate attenuated total reflectance device. The textural properties of the materials 
were determined by nitrogen sorption porosimetry by using a Micromeritics ASAP 2020. To 
perform the N2 measurements, the samples were previously degassed under vacuum for 24 h 
at room temperature. Thermogravimetry analysis (TGA) were performed in a Perkin Elmer 
Pyris Diamond TG/DTA analyzer, with 5 ºC/min heating ramps, from room temperature to 
600 ºC. The hydrodynamic size of mesoporous nanoparticles and protein capsules was 
measured by means of a Zetasizer Nano ZS (Malvern Instruments) equipped with a 633 nm 
“red” laser. Mass spectra were acquired with a Voyager DE-STR Biospectrometry MALDI-
TOF mass spectrometer. Transmission electron microscopy (TEM) was carried out with a 
JEOL JEM 1010 and JEOL JEM 2100 instruments operated at 100 kV and 200 kV, equipped 
with a CCD camera (KeenView Camera). Sample preparation was performed by dispersing in 
distilled water and subsequent deposition onto carbon-coated copper grids. A solution of 1% 
of phosphotungstic acid (PTA) pH 7.0 was employed as staining agent in order to visualize 
the protein capsules alone and attached on the mesoporous surface. Scanning electron 
microscopy (SEM) analyses were made on a JEOL 6400-LINK AN10000 microscope 
(Electron Microscopy Centre, UCM). The samples underwent Au metallization previous to 
observation. 
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Calculation procedures. 
The surface area was determined using the Brunauer-Emmett-Teller (BET) method and the 
pore volume, Vpore (cm3•g-1), was estimated from the amount of N2 adsorbed at a relative 
pressure around 0.99. The pore size distribution between 0.5 and 40 nm was calculated from 
the desorption branch of the isotherm by means of the Barrett-Joyner-Halenda (BJH) method. 
The mesopore size, Øpore (nm), was determined from the maximum of the pore size 
distribution curve. 
 
Synthesis of amino-functionalized mesoporous silica nanoparticles (MSN-XXN). 
Three different batches of mesoporous silica nanoparticles (MSNs) were synthesized 
according with the proportion of APTES in relation with TEOS employed in the process. The 
general method was as following: to a 500 mL round-bottom flask, 0.5 g of CTAB as a 
structure-directing agent, 240 mL of H2O (Milli-Q), 1.75 mL of NaOH (2 M) was added. The 
mixture was heated to 80ºC and stirred at 600 rpm. When the reaction mixture was stabilized 
at 80ºC, 12.2 mmol of a mixture of APTES/TEOS (10%, 20% or 30% APTES molar ratio, 
respectively) was added dropwise at 0.25mL/min rate. The white suspension obtained was 
stirred during further 2h at 80ºC. The reaction mixture was filtered and washed with 50 mL of 
H2O, and then three more times with 50 mL of EtOH. Finally, the surfactant was removed by 
ionic exchange using a solution of amonium nitrate (10 mg/mL) in 175 mL of ethanol (95%) 
at 65ºC overnight under magnetic stirring. The process was repeated three times. Samples 
were named as MSN-10N, MSN-20N or MSN-30N according with the amount of employed 
APTES. 
 
Loading IAA in MSN-XXN. 
25 mg of MMSN-XXN were placed in a three-neck round bottom flask and dried at 80ºC 
under vacuum for 24 h. Then, 2 mL of IAA aqueous solution (25 mg/mL) were added and the 
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suspension was stirred at room temperature for 24 h. After that time, the sample was filtered 
and washed smoothly two times with cold water (2x2 mL) in order to remove the IAA 
absorbed on the external surface. Finally, the products were dried under vacuum at 25ºC. 
 
Release of IAA from MSN-XXN. 
5 mg of IAA-loaded MSN-XXN were suspended in 0.5 mL of fresh PB pH 7.2 (100 mM) and 
placed on a Transwell® permeable support with 0.4 µm of polycarbonate membrane. The 
well was filled with 1.0 mL of PB pH 7.2 (100 mM) and the suspension was stirred at 150 
rpm during all the experiment. Every hour, the amount of IAA was determined using a Waters 
2695 HPLC separation module combined with a PDA detector and then, the media was 
replaced by other 1.0 mL of fresh buffer. The employed column was an XTerra® RP18 
4.6x150 mm (Waters) containing 5 µm of C18 silica beads, using injected volumes of 10 μL. 
The mobile phase was isocratic elution with 40:60% (A:B) of acetonitrile:H2O (75/25 v/v) (A) 
and NaOAc 20 mM (B) at 30ºC and flow rate of 0.5 mL/min. Under these conditions the 
retention time of the IAA was 3.0-3.20 min. Detection was performed by UV at 280 nm and 
chromatograms were recorded on an Endpower-2 integrator. 
 
Synthesis of acroylated HRPa. 
5 mg of HRP and 0.5 mg of 4-dimethylaminoantipyrine were dissolved in 1.8 mL of pH 8.5 
Na2CO3 (50 mM) at room temperature. To this solution, 2 mg of acrylic acid N-
hydroxysuccinimide ester dissolved in 20 µL of DMSO were added. The solution was stirred 
for 2 h. The protein was purified by centrifugal separation with 30KDa cut-off filters 
(AMICON® Ultra-2 30K) and washed three times with fresh pH 8.5 Na2CO3 (50mM) buffer. 
The protein was concentrated to final volume of 200 µL. 
 
Synthesis of HRP capsule (HRPc). 
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All of the acroylated protein solution obtained before was diluted with 2.8 mL of pH 8.5 
Na2CO3 (50 mM) buffer previously deoxygenated three times by freeze-pump-thraw cycles 
with N2. To this solution, a mixture of 8.5 mg of acrylamide, 15 mg of 2-aminoethyl 
methacrylate hydrochloride, 2.3 mg of N,N´-methylene(bisacrylamide) and 0.5 mg of 4-
dimethylaminoantipyrine dissolved in 2 mL of deoxygenated pH 8.5 Na2CO3 (50mM) buffer 
was added. The reaction media was placed in an orbital stirrer at 150 rpm for 10 min. After 
this time, 5 mg of ammonium persulfate (APS) and 5 µL of TMEDA dissolved in 30 µL of 
DMSO was added. The reaction mixture was stirred at 150 r.p.m during 90 min at room 
temperature. The protein capsule was purified by centrifugal separation with 50KDa cut-off 
filters (AMICON® Ultra-2 50K) and washed three times with pH 7.2 PB (100 mM) buffer. 
The protein was concentrated to final volume of 500 µL. 
 
Attachment of HRPc on the MSN-30N surface. 
2 mg of suberic acid bis(N-hydroxysuccinimide ester) dissolved in 50 µL of DMSO were 
added to a solution of 1 mg of HRPc in 1 mL of deoxygenated pH 7.2 PB (100 mM) buffer. 
The reaction mixture was placed in an orbital stirrer at 150 rpm at room temperature under 
nitrogen atmosphere during 30 min. After this time, the solution was filtered using a nylon 
membrane of 0.45 µm in order to remove the unreacted DSS and other salts precipitated in the 
water solution and the resulting liquid was added over a suspension of 20 mg of MSN-30N-
IAA in 1 mL of deoxygenated pH 7.2 PB (100mM) buffer. The mixture was stirred during 2 
hours under nitrogen atmosphere. The particles were filtered and washed smoothly two times 
with cold water, in order to remove the non-attached HRPc, and dried under N2 flux at room 
temperature. 
 
Cancer cell viability studies. 
Cytotoxicity of the enzymes (HRP native and HRPc): 
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The study of the cytotoxicity of HRP native and HRPc in the presence of increasing 
concentrations of enzyme was performed using the neuroblastoma cell line (NB1691-luc). 
Cells were seeded in 48-well plates at a density of 5000 cells•cm-2. Cells were exposed to 
different concentrations of HRP or HRPc during 4 hours at 37ºC, and 5% CO2. After that time, 
cells were washed and remained in culture for other 14 hours. Finally, cells were harvested 
and cell viability was determined by flow cytometry with 7AAD (Biolegends, San Diego, 
CA.) using the FACSCanto II flow cytometer and the FACSDiva software v6.1.2 (BD 
Biosciencies, San Jose, Ca.) 
 
Cytotoxicity of enzymes (HRP native and HRPc) using increased concentrations of IAA: 
This study was performed using the neuroblastoma cell line (NB1691-luc). Cells were seeded 
in 48-well plates at a density of 5000 cells•cm-2. Cells were exposed to different 
concentrations of IAA with a fixed concentration of enzyme of 0.01 mg•mL-1 (HRP native or 
HRPc, respectively) during 4 hours at 37ºC, and 5% CO2. After that time, cells were washed 
and remained in culture for other 14 hours. Finally, cells were harvested and cell viability was 
determined by flow cytometry with 7AAD (Biolegends, San Diego, CA.) using the 
FACSCanto II flow cytometer and the FACSDiva software v6.1.2 (BD Biosciencies, San Jose, 
Ca.) 
 
Cytotoxicity of the mesoporous silica devices (MSN-30N, MSN-30N-IAA and MSN-30N-IAA-
HRPc): 
In the case of the cytotoxic evaluation of the complete system, the studies were performed 
using the neuroblastoma cell line (NB1691-luc) and lymphoblastic NALM6 cell lines. Cells 
were seeded in 48-well plates at a density of 5000 cells•cm-2. Cells were exposed to different 
concentrations of MSN-30N, MSN-30N-IAA and MSN-30N-IAA-HRPc during 4 hours at 
37ºC, and 5% CO2. After that time, cells were washed and remained in culture for other 14 
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hours. The viability assay was carried out as the previous case. Results are shown as the mean 
of two independent replicates. 
 
Synthesis of MSN-30N labeled with RITC: 
1 mg of rhodamine B isocyanate dissolved in 40 µL of DMSO was added to a suspension of 
100 mg of MSN-30N particles in 2 mL of Milli-Q water. The suspension was stirred at 200 
rpm at room temperature during 12 hours. The particles were washed three times with water 
and dried overnight in a vacuum oven at 30ºC. 
 
Synthesis of HRPc-FITC: 
0.5 mg of FITC dissolved in 40 µL of DMSO were added to a solution of 5 mg of HRPa in 2 
mL of pH 8.5 Na2CO3 (50 mM) buffer. The suspension was placed in an orbital stirred at 100 
rpm and room temperature during 1 hour. After that time, the protein capsule was purified by 
centrifugal separation with 50KDa cut-off filters (AMICON® Ultra-2 50K) and washed three 
times with pH 7.2 PB (100 mM) buffer. The polymer capsule with the fluorescein labeled 
proteins and their attachment on the rhodamine B labeled mesoporous particles were 
performed following the similar procedures that are described above. The particles were dried 
by N2 flux at room temperature. The particles were called MSN-30N-HRPc-F-R. 
 
Internalization studies by confocal fluorescence microscopy: 
NB1691Luc cells were seeded on glass chamber slides (LabTek II, Nunc, Rochester, NY) and 
incubated with 0.5 mg/mL MSN-30N-HRPc-F-R for 4 hours. Internalization was stopped by 
washing cells with ice-cold PBS followed by two acid washes with 250mM NaCl, 100mM 
glycine  pH 2.5 to remove any adsorbed particules. Cells were then fixed with 4% PFA and 
mounted with DAPI-containing Fluoroshield (Sigma, St. Louis, MO). Images were capture 
with the Leica SP5 confocal microscope and the Leica LAS AF software. 
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